AZR earnings analysis
10-Q · Filed November 12, 2026 · Our reading of the company's report
The latest report
AZR remains a pre-revenue, preclinical biopharmaceutical company with a $64.6 million quarterly net loss, $118.6 million nine-month net loss, and $14.6 million of nine-month operating cash usage. Although approximately…
Read full summary
AZR remains a pre-revenue, preclinical biopharmaceutical company with a $64.6 million quarterly net loss, $118.6 million nine-month net loss, and $14.6 million of nine-month operating cash usage. Although approximately $25.5 million of 2026 equity proceeds and defined AT177 milestones provide near-term support, management states that additional financing is required and substantial dilution is possible. The unresolved material weakness, going-concern uncertainty, concentrated dependence on AT177, and commercialization timeline of 2032 or later keep the outlook bearish.
Reported figures
- Earnings per share
- $-4.52
What stood out
-
Large quarterly loss and accumulated deficit
The company reported a net loss of $64.6 million for the three months ended September 30, 2026, and an accumulated deficit of approximately $208.5 million as of September 30, 2026.
-
Operating cash burn increased
The company used $14.6 million of cash in operations during the nine months ended September 30, 2026, versus $6.5 million used during all of 2025, indicating materially higher cash-burn intensity.
-
Equity financing added liquidity
The company received approximately $25.5 million of net proceeds from equity issuances during 2026, providing some liquidity to fund operations and AT177 development.
-
AT177 development milestones identified
Management expects to submit an IND and initiate a Phase 1a SAD/MAD study for AT177 in the first half of 2027, with a proof-of-concept readout in ulcerative colitis patients expected in the first half of 2028.
-
Focused pipeline creates potential upside
The acquired colon-targeted AhR program represents greater than 90% of the fair value of assets acquired in the Merger, concentrating the company’s development exposure in AT177.
-
Large ulcerative colitis market
The company estimates the ulcerative colitis treatment market at approximately $7.5 billion to $10.8 billion, supporting a potentially substantial commercial opportunity if AT177 succeeds.
What to watch
-
Material weakness remains unresolved
Management identified a material weakness in internal control over financial reporting related to non-routine, complex transactions associated with the Merger, Financing and Azora Note Exchange. The CEO and CFO concluded that disclosure controls were not effective as of September 30, 2026.
-
Going-concern and funding risk
The company reported a net loss of $118.6 million and operating cash usage of $14.6 million for the nine months ended September 30, 2026. Management states that additional capital will be required to continue operations and AT177 development.
-
Long runway to potential revenue
The company has no approved products or product-sales revenue and states that commercialization is not expected to begin until 2032 or later, while research and development expenses are expected to increase.
-
Substantial potential equity dilution
At September 30, 2026, outstanding instruments included pre-funded warrants for 11,780,948 shares, Series A Preferred Stock convertible into 12,930,601 common shares, and warrants for 1,240,076 shares, creating substantial potential dilution.
-
AT177 remains preclinical
AT177 has not yet been tested in human clinical trials; the company expects only to submit an IND and begin Phase 1a studies in the first half of 2027, with no assurance of FDA acceptance, safety or efficacy.
-
Single-asset pipeline concentration
More than 90% of the fair value of assets acquired in the Merger is concentrated in one colon-targeted AhR program, so a failure or material setback in AT177 could disproportionately impair the value of the combined company.
Management's outlook
No numeric revenue or EPS guidance was provided in the 10-Q. Management expects to submit an IND for AT177 and initiate a Phase 1a SAD/MAD study in the first half of 2027, with a proof-of-concept readout expected in the first half of 2028; commercialization is not expected to begin until 2032 or later.
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.
See every AZR trade live.
The free pages stop at the last full session. Trader shows every trade as it prints.